Biognosys is a leader in next-generation proteomics, dedicated to transforming life sciences by developing and applying innovative mass spectrometry-based proteomics solutions. The company provides a comprehensive suite of services and products for high-content protein discovery, quantification, and biomarker identification. Biognosys supports researchers and pharmaceutical companies worldwide in their efforts to understand complex biological systems, discover new drug targets, and develop novel diagnostics and therapies. Their proprietary technologies and data analysis software, like Spectronaut®, enable deep and precise proteome coverage, empowering breakthroughs in various research areas including drug discovery, clinical research, and diagnostics development.
Serves as the central hub for research and development, global operations management, corporate strategy, software development, and customer support for European and international markets.
Located within the Bio-Technopark Schlieren-Zürich, providing access to a vibrant ecosystem of research institutions and biotech companies. The facility houses state-of-the-art mass spectrometry laboratories and data science infrastructure.
Emphasizes innovation, scientific excellence, collaboration, quality, and a customer-centric approach. Employees are typically highly skilled scientists, bioinformaticians, and professionals passionate about advancing proteomics and its applications.
Its location in a major European biotech cluster facilitates collaborations, talent acquisition, and access to cutting-edge research. It is the birthplace of Biognosys' core technologies and continues to drive innovation in the proteomics field.
Biognosys supports a global clientele through its headquarters in Switzerland and its US office in Massachusetts. The company provides its advanced proteomics services, software solutions (like Spectronaut® and TrueTarget™), and research collaboration opportunities to pharmaceutical companies, biotechnology firms, and academic research institutions across Europe, North America, Asia, and other regions worldwide. Their global reach is facilitated by direct engagement, a dedicated global commercial team, and a network of partners and distributors, ensuring access to their cutting-edge technologies for researchers globally.
Wagistrasse 21
Schlieren
Zurich
Switzerland
Address: 500 Cummings Center, Suite 4550, Beverly, MA 01915
To expand Biognosys' presence in the large North American life sciences market, offer localized customer support and scientific collaboration, and foster relationships with US-based research institutions and companies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Biognosys' leadership includes:
Biognosys has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major C-suite executive hires or departures widely announced by Biognosys in the last 12 months (ending May 2024), suggesting stability in top leadership. Any internal promotions or non-C-suite senior appointments may not have been broadly publicized.
Discover the tools Biognosys uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Biognosys likely uses standard corporate email formats. While specific internal patterns can vary, a common format for companies of this nature is [first].[last]@[companydomain.com] or [first_initial][last]@[companydomain.com]. For example, a contact like Jane Doe might have an email address such as jane.doe@biognosys.com.
[first].[last]@biognosys.com
Format
jane.doe@biognosys.com
Example
75%
Success rate
Business Wire • April 16, 2024
Biognosys launched its TrueDiscovery™ Deep Leukocyte Profiling platform, offering unbiased, deep profiling of over 5,000 proteins, including >1,000 surface proteins, across all major leukocyte cell types. This platform aims to accelerate drug discovery by identifying novel targets and biomarkers on immune cells....more
Business Wire • January 9, 2024
Biognosys and Thermo Fisher Scientific entered a co-marketing agreement to provide advanced plasma proteomics solutions for clinical research. The collaboration aims to combine Biognosys' expertise in proteomics services and software with Thermo Fisher's Orbitrap mass spectrometry platforms....more
Business Wire • November 7, 2023
Biognosys announced the expansion of its TrueTarget™ proteomics platform with new lysosome-focused capabilities, designed to support the discovery and development of targeted protein degrader (TPD) drugs by identifying proteins directed to the lysosome for degradation....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Biognosys, are just a search away.